A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer
Latest Information Update: 07 May 2023
At a glance
- Drugs UV 1 (Primary) ; Sargramostim
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms UV1-hTERT2012L
- Sponsors Ultimovacs AS
- 25 May 2022 According to an Ultimovacs AS media release, data from this study presented at the Journal for ImmunoTherapy of Cancer and was also presented as a poster at the Cancer Immunotherapy (CIMT) annual meeting.
- 10 May 2022 According to an Ultimovacs AS media release, data from this trial will be presented as a poster at the upcoming Cancer Immunotherapy (CIMT) annual meeting 2022.
- 10 May 2022 Results from long-term follow-up data published in an Ultimovacs AS Media Release.